Oramed Pharmaceuticals (ORMP) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Sionna Therapeutics (SION) over the past year, gaining 82.5% versus a loss of 87.8%. Sionna Therapeutics is the larger company by market cap ($175.6 million vs $169.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORMP | SION |
|---|---|---|
| Share price | $4.07 | $3.89 |
| Market cap | $169.30M | $175.63M |
| 1-day change | -2.63% | -4.66% |
| YTD return | +42.81% | -90.54% |
| 1-year return | +82.51% | -87.82% |
| 5-year return | -82.00% | — |
| P/E ratio (TTM) | 0.99 | — |
| EPS (TTM) | $4.13 | $-2.16 |
| Dividend yield | 6.13% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.00M | — |
| Net income (latest FY) | $64.05M | $-75.27M |
| Gross margin | 0.65% | — |
| Operating margin | -754.40% | — |
| Net margin | 3202.50% | — |
| 52-week high | $5.47 | $54.97 |
| 52-week low | $2.09 | $3.78 |
| Distance from 52-week high | -25.59% | -92.92% |
| Analyst consensus | none | hold |
| Avg. price target upside | +71.99% | +439.85% |
| Average volume | 188.22K | 2.22M |
| Shares outstanding | 41.60M | 45.15M |
| Employees | — | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed SION by 170.3 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (6.13% vs 0.00%).
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
ORMP vs SION FAQ
Which is bigger, Oramed Pharmaceuticals or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $175.63M compared with $169.30M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, ORMP or SION?
ORMP returned +82.51% over the past 12 months, compared with -87.82% for SION (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Oramed Pharmaceuticals or Sionna Therapeutics?
Oramed Pharmaceuticals pays a dividend yielding 6.13%, while Sionna Therapeutics does not currently pay a regular dividend.
Are Oramed Pharmaceuticals and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.